N-carbobenzoxy-α-isopropoxyglycine isopropyl ester | 150749-08-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-carbobenzoxy-α-isopropoxyglycine isopropyl ester
• 英文别名: a-isopropoxy-N-benzyloxycarbonylglycine isopropyl ester；propan-2-yl 2-(phenylmethoxycarbonylamino)-2-propan-2-yloxyacetate
• CAS: 150749-08-9
• 化学式: C₁₆H₂₃NO₅
• 分子量: 309.362
• InChiKey: YFTFBEMBHAOROV-UHFFFAOYSA-N

物化性质

• 沸点：
  437.6±45.0 °C(Predicted)
• 密度：
  1.114±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-carbobenzoxy-α-isopropoxyglycine isopropyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以94%的产率得到N-carbobenzoxy-α-isopropoxyglycine
  参考文献：
  名称：

  Preparation of Protected α-Alkoxyglycines

  摘要：

  N-Carbobenzoxy-alpha-alkoxyglycine esters were synthesized by H2SO4-catalyzed O-alkylation of N-carbobenzoxy-alpha-hydroxyglycine and also by base treatment of N-carbobenzoxy-N-chloroglycine methyl ester in the corresponding alcohol. Saponification of the protected alpha-alkoxyglycines gave free acids which can be used for the synthesis of alpha-alkoxyglycine residue-containing peptides.

  DOI：

  10.1080/00397919608003521
• 作为产物：
  描述：

  CBZ-甘氨酸甲酯 在 次氯酸叔丁酯 、 potassium isopropoxide 作用下， 以 甲醇 为溶剂， 反应 17.0h， 生成 N-carbobenzoxy-α-isopropoxyglycine isopropyl ester
  参考文献：
  名称：

  Preparation of Protected α-Alkoxyglycines

  摘要：

  N-Carbobenzoxy-alpha-alkoxyglycine esters were synthesized by H2SO4-catalyzed O-alkylation of N-carbobenzoxy-alpha-hydroxyglycine and also by base treatment of N-carbobenzoxy-N-chloroglycine methyl ester in the corresponding alcohol. Saponification of the protected alpha-alkoxyglycines gave free acids which can be used for the synthesis of alpha-alkoxyglycine residue-containing peptides.

  DOI：

  10.1080/00397919608003521

文献信息

• Identification of compounds that inhibit replication of human immunodeficiency virus
  申请人：Balzarini Maria Rene Jan

  公开号：US20050096319A1

  公开（公告）日：2005-05-05

  The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.

  本发明涉及一种新型化合物类别的发现，该化合物类别可以抑制人类免疫缺陷病毒（HIV）的复制，并提供了识别这些化合物的方法。具体而言，发现酶制备的α-羟基甘氨酰胺和合成制备的α-羟基甘氨酰胺可以抑制HIV在人血清中的复制。实施例包括识别抑制HIV的修饰甘氨酰胺化合物的方法，分离和合成修饰甘氨酰胺化合物的方法，以及包含这些化合物的治疗组合物。
• Compounds That Inhibit Replication Of Human Immunodeficiency Virus
  申请人：Balzarini Maria Rene Jan

  公开号：US20080076824A1

  公开（公告）日：2008-03-27

  The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HUV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.

  本发明涉及一种新型化合物类别的发现，该类化合物能够抑制人类免疫缺陷病毒（HIV）的复制，并提供了鉴定这些化合物的方法。具体来说，发现经酶法制备的α-羟基甘氨酰胺和人工合成的α-羟基甘氨酰胺能够抑制HIV在人血清中的复制。实施例包括鉴定抑制HUV的改性甘氨酰胺化合物的方法，分离和合成改性甘氨酰胺化合物的方法，以及包含这些化合物的治疗组合物。
• INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS
  申请人：Balzarini Jan Maria

  公开号：US20090170953A1

  公开（公告）日：2009-07-02

  The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.

  本发明涉及一种新型化合物类别的发现，这些化合物可以抑制人免疫缺陷病毒（HIV）的复制，并且还提供了识别这些化合物的方法。具体而言，发现了酶制备的α-羟基甘氨酰胺和合成制备的α-羟基甘氨酰胺可以在人血清中抑制HIV的复制。实施例包括识别抑制HIV的改性甘氨酰胺化合物的方法，分离和合成改性甘氨酰胺化合物的方法，以及包含这些化合物的治疗组合物。
• GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION
  申请人：TRIPEP AB

  公开号：EP1603546A1

  公开（公告）日：2005-12-14
• COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS
  申请人：TRIPEP AB

  公开号：EP1799222A2

  公开（公告）日：2007-06-27